ArticleVaccine2009
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.Journal of managed care & specialty pharmacy · 2020Pooled it
- Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk.Human vaccines & immunotherapeutics · 2026Article
- Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nature communications · 2024Article
- Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.Scientific reports · 2020Article
- Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.Journal of the International AIDS Society · 2019Article
- Article
- HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.Vaccine · 2018Article
- Structural Sensitivity in HIV Modeling: A Case Study of Vaccination.Infectious Disease Modelling · 2017Article
- The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.Vaccines · 2017Article
- The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review.PharmacoEconomics - open · 2017Article
- Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.Mathematical biosciences · 2016Article
- Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom.PloS one · 2014Article
- Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.Journal of general internal medicine · 2013Article
- The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.Annals of internal medicine · 2012Article
- Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.American journal of law & medicine · 2012Article
- Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.PloS one · 2012Article
- Mathematical models for the study of HIV spread and control amongst men who have sex with men.European journal of epidemiology · 2011Review
- Article
- Article
- HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Estimating the potential health benefits and expenditures of a partially effective HIV vaccine is an important consideration in the debate about whether HIV vaccine research should continue. We developed an epidemic model to estimate HIV prevalence, new infections, and the cost-effectiveness of vaccination strategies in the U.S. Vaccines with modest efficacy could prevent 300,000-700,000 HIV infections and save $30 billion in healthcare expenditures over 20 years. Targeted vaccination of high-risk individuals is economically efficient, but difficulty in reaching these groups may mitigate these benefits. Universal vaccination is cost-effective for vaccines with 50% efficacy and price similar to other infectious disease vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.